Clinical Trial Update: The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs. [Phase 3]

View source ↗

Summary

Phase 3 trial update of estrogen replacement to assess impact on coronary artery diameter in heart disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Disease

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Heart Disease | Phase 3 | Status: COMPLETED